发布求助
文献互助 智能选刊 最新文献

Australian Prescriber最新文献

筛选
英文 中文
Opicapone for Parkinson's disease. 新药：奥匹卡彭治疗帕金森病
IF 2.7
Australian Prescriber Pub Date : 2023-08-01 DOI: 10.18773/austprescr.2023.012
{"title":"Opicapone for Parkinson's disease.","authors":"","doi":"10.18773/austprescr.2023.012","DOIUrl":"10.18773/austprescr.2023.012","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46169008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia. 新药:Brexucabtagene自体甲醇治疗套细胞淋巴瘤、b细胞急性淋巴细胞白血病
IF 2.7
Australian Prescriber Pub Date : 2023-08-01 DOI: 10.18773/austprescr.2023.011
{"title":"Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia.","authors":"","doi":"10.18773/austprescr.2023.011","DOIUrl":"10.18773/austprescr.2023.011","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42866812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicines stewardship. 药品管理
IF 2.7
Australian Prescriber Pub Date : 2023-08-01 DOI: 10.18773/austprescr.2023.010
Elizabeth Su, David Fl Liew, Jane Donnelly, Rohan A Elliott
{"title":"Medicines stewardship.","authors":"Elizabeth Su, David Fl Liew, Jane Donnelly, Rohan A Elliott","doi":"10.18773/austprescr.2023.010","DOIUrl":"10.18773/austprescr.2023.010","url":null,"abstract":"<p><p>Medicines stewardship refers to coordinated strategies and interventions to optimise medicines use, usually within a specific therapeutic area. Medicines stewardship programs can reduce variations in practice and improve patient outcomes. Therapeutic domains for medicines stewardship are chosen to address frequently used drug classes associated with a high risk of adverse outcomes. Some examples include antimicrobial, opioid analgesic, anticoagulation and psychotropic stewardship. Common elements of successful stewardship programs include multidisciplinary leadership, stakeholder engagement, tailored communication strategies, behavioural changes, implementation science methodologies, and ongoing program monitoring, evaluation and reporting. Medicines stewardship is a continual quality improvement process that requires ongoing support and resources, as well as clinician and consumer engagement, to remain sustainable. It is critical for hospital-based medicines stewardship programs to consider impacts on care in the community when making and communicating changes to patient therapy. This ensures that stewardship efforts are sustained across transitions of care.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47949987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prescribing and peritoneal dialysis. 处方和腹膜透析
IF 2.7
Australian Prescriber Pub Date : 2023-06-01 DOI: 10.18773/austprescr.2023.001
Frank Reimann, Melinda Tomlins
{"title":"Prescribing and peritoneal dialysis.","authors":"Frank Reimann, Melinda Tomlins","doi":"10.18773/austprescr.2023.001","DOIUrl":"10.18773/austprescr.2023.001","url":null,"abstract":"<p><p>Peritoneal dialysis is a home-based therapy for patients with end-stage kidney disease. It is less efficient in removing solutes and fluid than haemodialysis but offers more flexibility and independence. Peritoneal transport characteristics affect the dialysis prescription. The timing of drug administration is independent of the dialysis process except for the administration of intraperitoneal antibiotics. Dose reductions should follow current recommendations for patients with kidney disease. Fluid overload is common in patients undergoing peritoneal dialysis. Residual kidney function can ameliorate this problem and needs to be preserved. Dialysis solutions with high glucose concentrations contribute to adverse metabolic effects. Peritoneal dialysis-related catheter complications and infections may require patients to transition to haemodialysis. Antifungal prophylaxis needs to be co-administered for the duration of antibiotic courses for any indication to reduce the risk of fungal peritonitis. Close communication with the patient's supervising dialysis unit is required.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41407428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Testing for COVID-19: a 2023 update. 诊断测试:COVID-19测试:2023年更新
IF 3.4
Australian Prescriber Pub Date : 2023-06-01 DOI: 10.18773/austprescr.2023.007
Ella M Meumann, Jennifer Mb Robson
{"title":"Testing for COVID-19: a 2023 update.","authors":"Ella M Meumann, Jennifer Mb Robson","doi":"10.18773/austprescr.2023.007","DOIUrl":"10.18773/austprescr.2023.007","url":null,"abstract":"<p><p>Nucleic acid amplification tests (NAATs), including polymerase chain reaction (PCR) assays, are more sensitive for the detection of SARS-CoV-2 than rapid antigen tests (RATS), and are the gold standard for diagnosis of acute COVID-19. However NAATs can remain positive for weeks following infection due to low-level shedding of non-viable viral fragments. RATs (in particular self-testing) are the mainstay of COVID-19 diagnosis due to their convenience, speed and high specificity. The sensitivity of RATs is highest within seven days of symptom onset. A negative RAT result may warrant a NAAT or repeat RAT for confirmation. The presence of spike antibodies is consistent with either vaccination or infection. Nucleocapsid antibodies suggest a previous infection. Serological tests measuring neutralising antibodies that infer immunity are not readily available.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46704825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex hormones and risk of coronary artery disease in women. 致编辑的信:性激素与女性冠状动脉疾病的风险
IF 2.7
Australian Prescriber Pub Date : 2023-06-01 DOI: 10.18773/austprescr.2023.009
Katie Harris, Sanne Ae Peters, Mark Woodward
{"title":"Sex hormones and risk of coronary artery disease in women.","authors":"Katie Harris, Sanne Ae Peters, Mark Woodward","doi":"10.18773/austprescr.2023.009","DOIUrl":"10.18773/austprescr.2023.009","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44929831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatments for atopic dermatitis. 特应性皮炎的治疗
IF 2.7
Australian Prescriber Pub Date : 2023-06-01 DOI: 10.18773/austprescr.2023.002
Gayle Ross
{"title":"Treatments for atopic dermatitis.","authors":"Gayle Ross","doi":"10.18773/austprescr.2023.002","DOIUrl":"10.18773/austprescr.2023.002","url":null,"abstract":"<p><p>Atopic dermatitis usually develops in childhood, but can occur in adults. Management involves drug and non-drug treatments to clear the skin. Not all patients with atopic dermatitis have allergies. Most patients have trigger factors that can be avoided. All patients should use soap substitutes and bath oils. Moisturisers are important for improving the condition of the skin. Topical corticosteroids are the main drug treatment. The choice of corticosteroid depends largely on the site of the atopic dermatitis. Topical calcineurin inhibitors can be considered for sensitive sites such as the face where potent topical corticosteroids are potentially harmful. Adjunctive treatments given during flares of dermatitis include bleach baths and wet dressings. Antihistamines may help to relieve itch. Phototherapy may be considered by a specialist for adults if there is inadequate response to treatment. Severe cases of atopic dermatitis may require systemic treatment. Immunosuppressants, such as ciclosporin, have been used and now dupilumab and upadacitinib are available for severe chronic atopic dermatitis.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42161727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treosulfan for acute myeloid leukaemia and myelodysplastic syndrome in adults, and malignant and non-malignant haematological diseases in children. 新药:曲硫芬用于成人急性髓性白血病和骨髓增生异常综合征，以及儿童恶性和非恶性血液病
IF 2.7
Australian Prescriber Pub Date : 2023-06-01 DOI: 10.18773/austprescr.2023.004
{"title":"Treosulfan for acute myeloid leukaemia and myelodysplastic syndrome in adults, and malignant and non-malignant haematological diseases in children.","authors":"","doi":"10.18773/austprescr.2023.004","DOIUrl":"10.18773/austprescr.2023.004","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45192289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Australian Prescriber: a new chapter. 澳大利亚处方集：新篇章。
IF 2.7
Australian Prescriber Pub Date : 2023-06-01 DOI: 10.18773/austprescr.2023.008
Leigh-Anne Claase
{"title":"<i>Australian Prescriber</i>: a new chapter.","authors":"Leigh-Anne Claase","doi":"10.18773/austprescr.2023.008","DOIUrl":"10.18773/austprescr.2023.008","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138489214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood pressure elevations in hospital. 医院血压升高。
IF 2.7
Australian Prescriber Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.068
Arduino A Mangoni, Elzbieta A Jarmuzewska, Genevieve M Gabb, Patrick Russell
{"title":"Blood pressure elevations in hospital.","authors":"Arduino A Mangoni,&nbsp;Elzbieta A Jarmuzewska,&nbsp;Genevieve M Gabb,&nbsp;Patrick Russell","doi":"10.18773/austprescr.2022.068","DOIUrl":"https://doi.org/10.18773/austprescr.2022.068","url":null,"abstract":"<p><p>Long-term hypertension control in the community significantly reduces cardiovascular risk. However, the benefit of controlling acute elevations of blood pressure in hospitalised patients is unclear. In-hospital elevations of blood pressure are relatively common and might not reflect poorly controlled blood pressure before admission. The measurement of blood pressure in hospital patients significantly differs from the best practice recommended for primary care and outpatients. Recent observational studies suggest that the pharmacological treatment of acute, asymptomatic, in-hospital elevations of blood pressure may have no benefit. However, it may increase the risk of in-hospital and post-discharge complications. Pending the development of robust inpatient measurement protocols, acute blood pressure elevations in hospitalised patients should not routinely require antihypertensive treatment in the absence of symptoms or acute end-organ damage. Rather, such elevations should facilitate follow-up of blood pressure and other cardiovascular risk factors after discharge.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/e7/austprescr-45-205.PMC9722348.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10740659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信